Literature DB >> 6277983

Discrepancy between thyroid-stimulating and thyrotropin-binding inhibitory activities of Graves' immunoglobulin Gs assessed in the mouse.

Y Shishiba, Y Ozawa, N Ohtsuki, T Shimizu.   

Abstract

TSH receptor binding-inhibiting (TBI) and thyroid-stimulating (TSI) activities of Graves' immunoglobulin Gs (IgGs) were measured using the murine TSH receptor (mTBI) and the McKenzie LATS bioassay. In contrast to the expectation that only the IgGs positive for LATS showed mTBI activity, mTBI activity was closely correlated with TBI activity measured at the human TSH receptor regardless of LATS potency (r = 0.79; P less than 0.01), indicating a lack of species specificity of IgG in this particular aspect. In 7 to 15 IgGs positive for both mTBI and LATS, there was a significant correlation between the 2 parameters (r = -0.89; P less than 0.01). However, 4 IgGs among the 15 were positive for mTBI but negative for LATS even when tested at 3- to 7-fold concentrations of IgG.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277983     DOI: 10.1210/jcem-54-4-858

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

2.  Graves' disease with neutropenia and marked splenomegaly: autoimmune neutropenia due to propylthiouracil.

Authors:  K Sato; M Miyakawa; D C Han; S Kato; Y Shibagaki; T Tsushima; K Shizume
Journal:  J Endocrinol Invest       Date:  1985-12       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.